WHO warns of second peak : COVID-19

▴ WHO warns of second peak : COVID-19
WHO warns of second peak of pandemic attack for the countries which are recovering from the infections

The World Health Organization (WHO) has warned that countries seeing a decline in COVID-19 infections could still face an "immediate second peak" if they let up too soon on measures to halt the outbreak.


During a media briefing yesterday, Mike Ryan, executive director of WHO's Health Emergencies Programme said that we are right in the middle of the first wave, globally and are still very much in a phase where the disease is actually on the way up. He added that epidemics often come in waves, which means that outbreaks could come back later this year in places where the first wave has subsided.


He added that there is also a chance that infection rates could rise once again more quickly if measures to halt the first wave were lifted too soon. Ryan warned that a second peak or wave could come during the normal influenza season, "which will greatly complicate things for disease control.


He said that countries in Europe and North America should continue to put in place the public health and social measures, the surveillance measures, the testing measures and a comprehensive strategy to ensure that we continue on a downwards trajectory and we don't have an immediate second peak.

Maria Van Kerkhove, a WHO infectious disease epidemiologist, said that a hallmark of coronaviruses is its ability to amplify in certain settings, its ability to cause transmission - or super spreading events.

Meanwhile,the World Health Organization (WHO) Director General Tedros Adnom Ghebreyesus yesterday said that it has temporarily suspended the clinical trial of Hydroxychloroquine (HCQ) on COVID-19 patients.

Earlier, in the last week, the Lancet Medical Journal published an observational study on HCQ and chloroquine and its effect on COVID-19 patients, who were hospitalized. The authors of the study reported that among patients receiving the drug, when used alone or with a macrolide, they estimated a higher mortality rate.

WHO had initiated the Solidarity Trial, to evaluate the safety and efficacy of four drugs and drug combinations against COVID-19, which include HCQ.

The Executive Group of the Solidarity Trial, representing 10 of the participating countries, met earlier this week and has agreed to review a comprehensive analysis and critical appraisal of all evidence available globally. The review will consider data collected so far in the Solidarity Trial and in particular robust randomized available data, to adequately evaluate the potential benefits and harms from this drug.

Mr Tedros, further said that the other arms of the trial are continuing and this concern relates to the use of Hydroxychloroquine and chloroquine in COVID-19. He reiterated that these drugs are accepted as generally safe for use in patients with autoimmune diseases or malaria.

According to the WHO, over 400 hospitals in 35 countries are actively recruiting patients and nearly 3,500 patients have been enrolled from 17 countries under the Solidarity Trial.

Tags : #HCQ #COVID-19 #WHO #SecondWave #MikeRyan

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

10 PCOS Warning Signs That Need Your AttentionDecember 27, 2024
Experts Dub 2024 as the Year of Technologies and Innovations in Healthcare; Stress on further Integration of Technologies December 27, 2024
Aakash Healthcare Partners with Japan for Groundbreaking Surgical Intervention: A Global Collaboration to Revolutionize Cardiovascular CareDecember 26, 2024
Traditional Medicine Goes Global: How Ayush 2024 Reimagined WellnessDecember 26, 2024
Aster Guardians Global Nursing Award 2025 worth INR 2 Crore now open for nominations worldwide December 26, 2024
Holiday Season Round the Corner? 6 Daily Habits That Could Be The Reason Behind Your Fatty LiverDecember 26, 2024
Healing the Nation: Doctors as Architects of a Healthier FutureDecember 26, 2024
Brewing Health Benefits: Can Coffee and Tea Help Fight Head and Neck Cancers?December 26, 2024
Seven-Year-Old Fights Back Against Rare Autoimmune DiseaseDecember 26, 2024
Olympus Named to Dow Jones Sustainability World Index for the Fourth Consecutive YearDecember 26, 2024
American Oncology Institute (AOI) in Nagpur Restores Mobility with KyphoplastyDecember 26, 2024
Sanjeevani Healthcare & Wellness Expo 2024: A Dynamic Platform for Global Healthcare CollaborationDecember 23, 2024
Ranitidine: Saviour or Suspect? The Truth Behind the Stomach Acid RemedyDecember 23, 2024
From One-Size-Fits-All to Precision Medicine: The New Hope for Rare Bone Cancer PatientsDecember 23, 2024
World Meditation Day: India’s Gift of Peace to a Chaotic WorldDecember 23, 2024
Breaking New Ground in Migraine Care: A Landmark Session on Diagnosis and TreatmentDecember 23, 2024
Black Angels remind us of centuries of injustices plaguing the TB responseDecember 20, 2024
Healthcare Startups to Watch Out for in 2025December 20, 2024
Biobank Blueprint: Redefining Diabetes Diagnosis and Treatment in IndiaDecember 20, 2024
The Future of Malaria Prevention: Can This Vaccine Eliminate the Disease?December 20, 2024